Photo by nci from unsplash
Tebentafusp, a T cell-redirecting, bispecific-antibody-targeting, HLA∗02:01-restricted gp100 peptide and CD3, induces T cells to kill glycoprotein 100 (gp100)-expressing tumor cells. Tebentafusp is the first T cell engager to show a statistically significant overall… Click to show full abstract
Tebentafusp, a T cell-redirecting, bispecific-antibody-targeting, HLA∗02:01-restricted gp100 peptide and CD3, induces T cells to kill glycoprotein 100 (gp100)-expressing tumor cells. Tebentafusp is the first T cell engager to show a statistically significant overall survival improvement for the treatment of patients with solid tumors, and this has been reported in the New England Journal of Medicine.
Keywords:
engagers solid;
solid tumors;
cell engagers;
tumors kick;
kick door;
cell
Journal Title: Cancer cell
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer cell
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!